**Core Concept:**
The question is testing the understanding of a neurotransmitter reuptake inhibitor and its action on sodium channels. Neurotransmitters are chemical messengers that transmit signals across the synaptic cleft between neurons. The primary neurotransmitters involved in this question are dopamine and norepinephrine, which are both involved in the regulation of mood, cognition, and cardiovascular function. Reuptake inhibitors work by preventing the reabsorption of these neurotransmitters, thereby increasing their concentration in the synaptic cleft and enhancing their effect. Additionally, the question mentions an action on sodium channels, which relates to the effects of certain neurotransmitter inhibitors on cardiac tissue.

**Why the Correct Answer is Right:**
The correct answer, option D, is the drug Fluoxetine. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI), but it also has a noradrenaline reuptake inhibitory action. It is a selective inhibitor of the serotonin transporter (SERT), the protein responsible for the reuptake of serotonin into presynaptic neurons. The inhibition of SERT leads to increased extracellular concentrations of serotonin, which can enhance synaptic transmission and modulate mood, cognition, and appetite. Fluoxetine's noradrenaline reuptake inhibitory action contributes to its clinical effects on mood disorders, anxiety, and cognitive function.

Fluoxetine also inhibits the voltage-gated sodium channels in cardiac myocytes, which can cause QT interval prolongation and torsades de pointes in susceptible individuals. This is relevant because certain neurotransmitter inhibitors may have unintended effects on cardiac function, particularly in patients with pre-existing conditions or those taking medications that affect cardiac conduction.

**Why Each Wrong Option is Incorrect:**
A. Venlafaxine is a serotonin-noradrenaline reuptake inhibitor (SNRI), which is a different class of antidepressant from Fluoxetine (SSRI). SNRIs inhibit both serotonin and noradrenaline reuptake, while SSRIs only inhibit serotonin reuptake. Venlafaxine does not have the same cardiac risk profile as Fluoxetine due to its broader spectrum of action on neurotransmitter reuptake.

B. Escitalopram (Cipramil) is another SSRI, similar to Fluoxetine, but it differs in its mechanism of action and cardiac risk profile. Escitalopram has a higher selectivity for serotonin reuptake inhibition and does not significantly inhibit noradrenaline reuptake or cardiac sodium channels. As a result, it does not share the same cardiac risk profile as Fluoxetine.

C. Imipramine is an older tricyclic antidepressant with broad-spectrum antidepressant and anti-anxiety properties. It inhibits both serotonin and noradrenaline reuptake and also blocks voltage-gated sodium channels in cardiac myocytes, which can lead to QT interval prolongation and torsades de pointes arrhythmias. Imipramine shares the cardiac risk profile with Fluoxetine due to its broader spectrum of action.